|
1
|
Agustí A and Vestbo J: Current
controversies and future perspectives in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 184:507–513.
2011.PubMed/NCBI
|
|
2
|
Dalal AA, Liu F and Riedel AA: Cost trends
among commercially insured and Medicare Advantage-insured patients
with chronic obstructive pulmonary disease: 2006 through 2009. Int
J Chron Obstruct Pulmon Dis. 6:533–542. 2011. View Article : Google Scholar
|
|
3
|
Lopez AD, Shibuya K, Rao C, et al: Chronic
obstructive pulmonary disease: current burden and future
projections. Eur Respir J. 27:397–412. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rabe KF, Hurd S, Anzueto A, et al; Global
Initiative for Chronic Obstructive Lung Disease. Global strategy
for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir
Crit Care Med. 176:532–555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parr DG, White AJ, Bayley DL, Guest PJ and
Stockley RA: Inflammation in sputum relates to progression of
disease in subjects with COPD: a prospective descriptive study.
Respir Res. 7:1362006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
GOLD Executive Committee. Global strategy
for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease (Revised 2011) [EB/OL]. http://www.goldcopd.comuri.
Accessed February 22, 2012
|
|
7
|
Asadullah K, Sterry W and Volk HD:
Interleukin-10 therapy - review of a new approach. Pharmacol Rev.
55:241–269. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hacievliyagil SS, Gunen H, Mutlu LC,
Karabulut AB and Temel I: Association between cytokines in induced
sputum and severity of chronic obstructive pulmonary disease.
Respir Med. 100:846–854. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ko FW, Leung TF, Wong GW, et al:
Measurement of tumor necrosis factor-alpha, leukotriene B4, and
interleukin 8 in the exhaled breath condensate in patients with
acute exacerbations of chronic obstructive pulmonary disease. Int J
Chron Obstruct Pulmon Dis. 4:79–86. 2009.
|
|
10
|
O’Donnell R, Breen D, Wilson S and
Djukanovic R: Inflammatory cells in the airways in COPD. Thorax.
61:448–454. 2006.
|
|
11
|
Kochetkova EA, Volkova MV, Surovenko TN
and Gel’tser BI: Cytokine status in patients with chronic
obstructive pulmonary diseases and its relationship with bone
tissue functional state. Ter Arkh. 76:23–27. 2004.(In Russian).
|
|
12
|
Calverley PM, Anderson JA, Celli B, et al;
TORCH investigators. Salmeterol and fluticasone propionate and
survival in chronic obstructive pulmonary disease. N Engl J Med.
356:775–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
COPD Working Group of Chinese Medical
Association respiratory disorder branch. Guidelines for the
Diagnosis and Treatment of COPD (2007 Revised Edition). Chin J
Tuberc Respir Dis. 30:8–17. 2007.(In Chinese).
|
|
14
|
Chen HZ: Practical Internal Medicine. 11th
edition. People’s Health Publishing House; Beijing: pp. 1449–1452.
2001
|
|
15
|
Oudin S and Pugin J: Role of MAP kinase
activation in interleukin-8 production by human BEAS-2B bronchial
epithelial cells submitted to cyclic stretch. Am J Respir Cell Mol
Biol. 27:107–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Powrie DJ, Wilkinson TM, Donaldson GC, et
al: Effect of tiotropium on sputum and serum inflammatory markers
and exacerbations in COPD. Eur Respir J. 30:472–478. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung KF: Inflammatory mediators in
chronic obstructive pulmonary disease. Curr Drug Targets Inflamm
Allergy. 4:619–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gong MN, Thompson BT, Williams PL, et al:
Interleukin-10 polymorphism in position -1082 and acute respiratory
distress syndrome. Eur Respir J. 27:674–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson SJ, Wallin A, Della-Cioppa G,
Sandström T and Holgate ST: Effect of budesonide and formoterol on
NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir
Crit Care Med. 164:1047–1052. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kersul AL, Iglesias A, Ríos Á, et al:
Molecular mechanisms of inflammation during exacerbations of
chronic obstructive pulmonary disease. Arch Bronconeumol.
47:176–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takanashi S, Hasegawa Y, Kanehira Y, et
al: Interleukin-10 level in sputum is reduced in bronchial asthma,
COPD and in smokers. Eur Respir J. 14:309–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burgess JL, Nanson CJ, Hysong TA, Gerkin
R, Witten ML and Lantz RC: Rapid decline in sputum IL-10
concentration following occupational smoke exposure. Inhal Toxicol.
14:133–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu SX, Zhang GJ, Wang HQ, Chen SS and Chu
HY: Effect of inhaled glucocorticoids/long-acting β2-agonist on
chronic obstructive pulmonary disease. International Journal of
Respiration. 29:129–131. 2009.(In Chinese).
|
|
24
|
Barnes NC, Qiu YS, Pavord ID, et al;
SCO30005 Study Group. Antiinflammatory effects of
salmeterol/formoterol propionate in chronic obstructive lung
disease. Am J Respir Crit Care Med. 173:736–743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bourbeau J, Christodoulopoulos P, Maltais
F, Yamauchi Y, Olivenstein R and Hamid Q: Effect of
salmeterol/fluticasone propionate on airway inflammation in COPD: a
randomised controlled trial. Thorax. 62:938–943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Celli BR, Thomas NE, Anderson JA, et al:
Effect of pharmacotherapy on rate of lung function in chronic
obstructive pulmonary disease: results from the TORCH study. Am J
Respir Crit Care Med. 178:332–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fenton C and Keating GM: Inhaled
salmeterol/fluticasone propionate: a review of its use in chronic
obstructive pulmonary disease. Drugs. 64:1975–1996. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marwick VM and Chung KF: Glucocorticoid
insensitivity as a future target of therapy for chronic obstructive
pulmonary disease. Int J Chron Obstruct Pulmon Dis. 5:297–309.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patel IS, Roberts NJ, Lloyd-Owen SJ,
Sapsford RJ and Wedzicha JA: Airway epithelial inflammatory
responses and clinical parameters in COPD. Eur Respir J. 22:94–99.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Armstrong J, Harbron C, Lea S, et al:
Synergistic effects of p38 mitogen-activated protein kinase
inhibition with a corticosteroid in alveolar macrophages from
patients with chronic obstructive pulmonary disease. J Pharmacol
Exp Ther. 338:732–740. 2011. View Article : Google Scholar
|
